Non-small cell lung cancer (NSCLC) remains one of the toughest cancers to treat, but bispecific antibodies (BsAbs) are changing the game. Unlike traditional therapies, BsAbs are engineered to target two different antigens simultaneously, enhancing precision and boosting immune response. This dual-targeting approach allows BsAbs to not only block cancer growth signals but also engage immune cells more effectively, leading to higher tumor-killing efficiency and reduced resistance.
The potential of bispecific antibodies in NSCLC lies in their ability to combine the best of immunotherapy and targeted therapy. By bridging tumor cells with immune cells like T cells, BsAb...
